Display options
Share it on

Allergy Asthma Immunol Res. 2017 May;9(3):237-246. doi: 10.4168/aair.2017.9.3.237.

Anti-Interleukin-9 Antibody Increases the Effect of Allergen-Specific Immunotherapy in Murine Allergic Rhinitis.

Allergy, asthma & immunology research

Ji Hyeon Shin, Do Hyun Kim, Boo Young Kim, Sung Won Kim, Se Hwan Hwang, Joohyung Lee, Soo Whan Kim

Affiliations

  1. Department of Otolaryngology-Head and Neck Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea.
  2. Department of Otolaryngology-Head and Neck Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea. [email protected].

PMID: 28293930 PMCID: PMC5352575 DOI: 10.4168/aair.2017.9.3.237

Abstract

PURPOSE: Interleukin (IL)-9 induces allergic responses; however, the roles of anti-IL-9 antibody in the induction of tolerance remain unclear. This study investigated the effects of anti-IL-9 antibody on oral tolerance (OT) in a mouse model of allergic rhinitis (AR).

METHODS: BALB/c mice were divided into 4 groups: the control, AR, OT, and OT with anti-IL-9 antibody (OT+IL9AB) groups. Ovalbumin (OVA) was used for sensitization and challenge. Mice in the OT and OT+IL9AB groups were fed OVA for immunotherapy. During immunotherapy, OT+IL9AB mice were injected with anti-IL-9 antibody. Allergic symptoms, tissue eosinophil counts, and serum OVA-specific immunoglobulin E (IgE) were measured. The mRNA expressions of cytokines and transcription factors of T cells of nasal mucosa were determined by real-time polymerase chain reaction (PCR). The protein levels of GATA3, ROR-γt, and Foxp3 in nasal mucosa were determined by Western blot. CD4⁺CD25⁺Foxp3⁺ T cells in the spleen were analyzed by flow cytometry.

RESULTS: Administration of anti-IL-9 antibody decreased allergic symptoms, OVA-specific IgE levels, and eosinophil counts. In addition, it inhibited T-helper (Th) 2 responses, but had no effect on Th1 responses. Protein levels of ROR-γt and mRNA levels of PU.1 and ROR-γt were reduced by anti-IL-9 antibody. Anti-IL-9 antibody increased Foxp3 and IL-10 mRNA expression, Foxp3 protein, and induction of CD4⁺CD25⁺Foxp3⁺ T cells.

CONCLUSIONS: Anti-IL-9 antibody decreased allergic inflammation through suppression of Th2 and Th17 cells. Anti-IL-9 antibody enhanced the tolerogenic effects of regulatory T cells. These results suggest that anti-IL-9 antibody might represent a potential therapeutic agent for allergen immunotherapy in patients with uncontrolled allergic airway disease.

Copyright © 2017 The Korean Academy of Asthma, Allergy and Clinical Immunology · The Korean Academy of Pediatric Allergy and Respiratory Disease

Keywords: Allergic rhinitis; interleukin-9; mouse; oral tolerance; regulatory T cells

Conflict of interest statement

There are no financial or other issues that might lead to conflict of interest.

References

  1. Immunology. 1998 Oct;95(2):193-9 - PubMed
  2. Nat Immunol. 2010 Jun;11(6):527-34 - PubMed
  3. Immunology. 2014 Nov;143(3):396-405 - PubMed
  4. Eur J Immunol. 2011 Aug;41(8):2197-206 - PubMed
  5. J Immunol. 2010 Oct 1;185(7):4095-100 - PubMed
  6. Adv Biomed Res. 2014 May 28;3:127 - PubMed
  7. Expert Rev Clin Immunol. 2015;11(12):1321-33 - PubMed
  8. J Allergy Clin Immunol. 2015 Aug;136(2):433-40.e1 - PubMed
  9. Cell Cycle. 2009 Dec;8(23):3798-9 - PubMed
  10. Nat Med. 2012 May 04;18(5):736-49 - PubMed
  11. Nature. 2006 Aug 31;442(7106):997-1002 - PubMed
  12. Asia Pac Allergy. 2014 Oct;4(4):212-21 - PubMed
  13. Allergy Asthma Immunol Res. 2015 Mar;7(2):158-66 - PubMed
  14. Medicina (Kaunas). 2015 ;51(1):10-7 - PubMed
  15. Proc Natl Acad Sci U S A. 2009 Aug 4;106(31):12885-90 - PubMed
  16. Curr Opin Allergy Clin Immunol. 2015 Feb;15(1):41-8 - PubMed
  17. J Immunol. 2011 Jan 1;186(1):83-91 - PubMed
  18. Allergy Asthma Proc. 2011 Mar-Apr;32(2):83-94 - PubMed
  19. World Allergy Organ J. 2015 May 14;8(1):17 - PubMed
  20. Respir Physiol Neurobiol. 2009 Jan 1;165(1):13-21 - PubMed
  21. Expert Rev Clin Immunol. 2015;11(11):1205-17 - PubMed
  22. Allergy Asthma Immunol Res. 2013 Jul;5(4):189-96 - PubMed
  23. Allergy. 2011 Oct;66(10):1312-21 - PubMed
  24. Immunol Rev. 2005 Aug;206:232-59 - PubMed
  25. Nat Rev Immunol. 2015 May;15(5):271-82 - PubMed
  26. J Allergy Clin Immunol. 2013 Apr;131(4):1048-57, 1057.e1-2 - PubMed
  27. BMC Pulm Med. 2011 Feb 28;11:14 - PubMed
  28. J Allergy Clin Immunol. 2011 Dec;128(6):1357-1360.e5 - PubMed
  29. J Allergy Clin Immunol. 2006 Feb;117(2):283-90 - PubMed
  30. Immunity. 2013 Feb 21;38(2):360-72 - PubMed
  31. BMC Pulm Med. 2015 Oct 14;15:122 - PubMed
  32. J Allergy Clin Immunol. 2012 Apr;129(4):1000-10.e3 - PubMed
  33. Am J Respir Cell Mol Biol. 2007 Aug;37(2):202-9 - PubMed
  34. Am J Respir Crit Care Med. 2011 Apr 1;183(7):865-75 - PubMed
  35. Nat Rev Immunol. 2015 May;15(5):295-307 - PubMed
  36. Allergy. 2015 Jul;70(7):727-54 - PubMed
  37. Allergy Asthma Immunol Res. 2013 Jul;5(4):197-206 - PubMed
  38. J Allergy Clin Immunol. 2013 May;131(5):1288-96.e3 - PubMed
  39. Otolaryngol Head Neck Surg. 2010 Mar;142(3):370-5 - PubMed
  40. Nat Immunol. 2012 Jun 19;13(7):637-41 - PubMed
  41. Trends Immunol. 2014 Feb;35(2):61-8 - PubMed
  42. Immunity. 2010 Aug 27;33(2):192-202 - PubMed
  43. Immunobiology. 2002 Oct;206(4):408-23 - PubMed
  44. Nat Immunol. 2013 Jun;14(6):536-42 - PubMed
  45. Ann N Y Acad Sci. 2002 Apr;958:47-58 - PubMed
  46. Respir Res. 2013 Sep 19;14:93 - PubMed
  47. Allergy Asthma Immunol Res. 2016 May;8(3):191-7 - PubMed
  48. Allergy. 2014 Aug;69(8):1068-76 - PubMed

Publication Types